Prospective, multicenter clinical study of rmhTNF-NC injection in the treatment of Chinese malignant pleural effusion or peritoneal effusion patients
Shukui QIN,Xiufeng LIU,Jun MA,Jun ZHU,Weijing ZHANG,Xiaoqing LIU,Jianying ZHOU,Kangsheng GU,Yong LIN,Changping WU,Zhixiang ZHUANG,Qingming SHI,Xianping CHENG,Shuiping MENG,Qun CHEN,Heping ZHAO,Yangyi BAO,Xia YUAN,Cantu FANG,Bairong ZENG,Zhidong WANG,Qingliang FENG,Chuntang WANG,Xigui YANG,Youshan CHEN,Yanmin WU
2016-01-01
Abstract:Objective To investigate and confirm the clinical efficacy and safety of recombinant mutant human tumor necrosis factor-NC ( rhTNF-NC,Tianenfu) injection in the treatment of malignant pleural effusion and peritoneal effusion. Methods It was a perspective,open-label,single arm and multi-center study,conducted in 82 cancer centers in China. From April 25 2013 to August 31 2015, a total of 985 patients with middle and large amount of malignant pleural effusion or peritoneal effusion were enrolled into this study. rmhTNF-NC was infused intralpeurally at a dose of 300 KU each time at d1 , d4 , d7 , or d10 , and 3-4 times was regarded as one course. The efficacy and safety were evaluated according WHO and NCI CTC AE 3. 0 criterion respectively. Results Among 985 pa-tients, the efficacy could be evaluated in 916 cases ( 93. 00%) with dropout rate of 7. 00%. In 916 patients, the objective response rate ( ORR) was 62. 44% and disease control rate ( DCR) was 97. 27%. ORR of 614 malignant pleural effusion cases and 302 malignant peritoneal effusions cases were 70. 52% and 46. 03% respectively( P<0. 05) . Two-classification Logistic regression showed that effusion position, treatment condition ( initial treatment vs. retreatment) were independent factors influencing ORR of rmhTNF-NC in the treat-ment of malignant pleural effusion or peritoneal effusion( P<0. 05) , treatment condition was the independent factor influencing ORR of rmhTNF-NC in the treatment of malignant pleural effusion ( P<0. 05) , and gender, PS score before treatment and treatment condition were independent factors influencing ORR of rmhTNF-NC in the treatment of malignant peritoneal effusion(P<0. 05). The major ad-verse effects (AE) were fever (14. 01%) and chill (10. 05%). Other AE included fatigue(1. 02%), pain(0. 81%), constipation (0. 61%), transaminase lift(0. 51%),decreased renal function(0. 30%), shortness of breath(0. 20%), rashes(0. 20%)and leuco-penia( 0. 20%) . The vast of those AE was in grade 1 or grade 2, and could be reversible. There was no grade 4 AE and drug related death happened. Conclusion rmhTNF-NC injection is effective and safe in control of malignant pleural effusions or peritoneal effu-sions, especially better in the early treat and malignant pleural effusions patients, with mild and tolerable adverse effects.